| IDEAYA BIOSCIENCE DL-,01 |
| USA |
| Gesundheit |
| US45166A1025 / A2PJPB |
| 30J (Frankfurt) / IDYA (NASDAQ) |
| FRA:30J, ETR:30J, 30J:GR, NASDAQ:IDYA |
| - |
| https://www.ideayabio.com.. |
|
Ideaya Biosciences Inc. is a precision medicine oncology company that discovers and develops targeted therapeutics for patient populations identified through molecular diagnostics. Its pipeline features IDE196, a protein kinase C inhibitor in Phase 2..
>Volltext.. |
| 2165.61 Mio. EUR |
| 1605.11 Mio. EUR |
| 195.51 Mio. EUR |
| -155.24 Mio. EUR |
| -121.56 Mio. EUR |
| -1.37 EUR |
| 24.82 Mio. EUR |
| 136.71 Mio. EUR |
| - |
| 10.35 |
| 2913.36% |
| 57.29% |
| - |
| - |
| - |
| - |
| IDEAYA |
| 09.06.26 |
|
||||
|